Komori
Mitsubishi Chemical Group (4188) · InitiativeAchieved

Making Tanabe Mitsubishi Pharma a wholly owned subsidiary

First written in FY2020-Q3. 1 of 2 entries say "Achieved", first in FY2020. Latest entry: FY2020.

2entries
1years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2020-Q32020: 22020
Same theme, other companies

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2020AchievedAnnual report

    「Upon the share sale demand taking effect on 2 March 2020, the company acquired 47,308 thousand common shares of the company for ¥95,088 million, excluding transaction costs, making the company a wholly owned subsidiary.」

    Regarding Tanabe Mitsubishi Pharma, the share sale demand following the tender offer took effect on 2 March 2020, completing the process of making it a wholly owned subsidiary.
  2. FY2020-Q3First statedAnnual report

    「As part of a transaction to make Tanabe Mitsubishi Pharma Co., Ltd., a consolidated subsidiary, a wholly owned subsidiary, the company conducted a tender offer for the company's shares from 19 November 2019 to 7 January 2020. The tender offer was successful because the total number of shares tendered on the closing date was at least the minimum number of shares to be purchased. On 15 January 2020, the company acquired 197,355 thousand common shares of the company for ¥396.7 billion, excluding transaction costs, increasing its percentage interest in voting equity from 56.4% to 91.6%. The company plans for the company to become a wholly owned subsidiary upon the effective date of the share sale demand, scheduled for 2 March 2020. The consideration for the acquisition of the company's common shares through the share sale demand is expected to be ¥95.1 billion. With respect to financing for these transactions, short-term borrowings are scheduled to be switched to long-term borrowings or bonds within one year, and no equity financing such as a new share issuance is contemplated.」

    The tender offer aimed at making Tanabe Mitsubishi Pharma a wholly owned subsidiary was successful, and on 15 January 2020 the company acquired 197,355 thousand shares for ¥396.7 billion, raising its ownership interest from 56.4% to 91.6%. The share sale demand was scheduled to take effect on 2 March 2020, with consideration for the acquisition of the remaining non-controlling interest expected to be ¥95.1 billion. Financing is to be switched from short-term borrowings to long-term borrowings or bonds, and no new share issuance or other equity financing is contemplated.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Mitsubishi Chemical Group yet.